NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
abpro.comAbpro Holdings plans to initiate clinical trials for ABP-102/CT-P72 in the first half of 2026, aiming to redefine treatment options for HER2-positive cancers.
clinical readout